No­var­tis man­u­fac­tur­ing fa­cil­i­ty in North Car­oli­na gets FDA all-clear to pro­duce, ship gene ther­a­pies

Just one day af­ter Vas Narasimhan an­nounced $1 bil­lion in cuts amid a com­pa­ny-wide re­struc­tur­ing, the Amer­i­can-Swiss phar­ma re­ceived FDA clear­ance to pro­duce its spinal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER